Changes in Net Portal Nutrient Flux in Response to Weaning Transition and Ionophore Supplementation in Dairy Calves

Dairy calf weaning is associated with ketone concentrations that exceed the levels occurring in adults, and weaning represents a potential energy loss that may be mitigated by ionophore supplementation. To assess the effects of weaning and ionophore supplementation on net nutrient flux across portal-drained viscera (PDV) tissues in dairy calves, concentrations of glucose, acetoacetate (ACAC), beta-hydroxybutyrate (BHBA), nonesterified fatty acids, volatile fatty acids, lactate, pyruvate, insulin, and glucagon and PDV flux rates were determined in Jersey bull calves (n = 19) at 35, 56, 84, and 112 d of age. Calves were randomly assigned at birth to either a commercial pelleted starter without (CON) or with lasalocid (TRT; 83 mg/kg of dry matter). Calves were fed only milk replacer from d 3 to 34 (d 3 to 20 = 454 g/d; d 21 to 34 = 568 g/d). After blood sampling on d 35, calves received replacer (d 35 to 41 = 454 g/d; d 42 to 48 = 227 g/d) and had free access to the CON or TRT starter, and from d 49 to 112 they received CON or TRT ad libitum. Catheters were implanted in the portal vein and in the mesenteric vein and artery between d 21 and 28. Blood flow was measured by continuous infusion of p-aminohippurate into the mesenteric vein. Six serial samples were taken at 30-min intervals from the arterial and portal vein catheters simultaneously. Portal blood flow increased with age but did not differ between CON and TRT calves. Glucose was released preweaning and was extracted postweaning by PDV, but was not affected by ionophore. The portal flux of nonesterified fatty acids was not different from zero during any of the 4 sample ages. Fluxes of ACAC and BHBA in CON and TRT calves went from no measurable flux preweaning to a postweaning PDV release that peaked at d 84, but the d-84 release of ACAC and BHBA was lower in TRT calves. The portal flux of volatile fatty acids increased with age, and PDV release of both butyrate and propionate was lower at d 84 in TRT than in CON calves. However, TRT calves had a greater PDV release of lactate on d 84, partially compensating for the lower release of propionate. Glucagon was greater in CON than in TRT calves at d 84 and could be a response to the elevated ketogenesis observed in CON calves during this period. Changes in the metabolic profile and nutrient flux of transition calves were demonstrated in response to weaning and ionophore supplementation. Inclusion of an ionophore appeared to moderate alimentary output at a postweaning period (d 84) at which ketone concentrations have the potential to exceed the whole animal capacity for utilization.

Efficacy of ionophores in cattle diets for mitigation of enteric methane

Use of ionophores in cattle diets has been proposed as a strategy for mitigation of enteric CH4 emissions. Short- and long-term effects of feeding a single ionophore (monensin) or rotation of 2 ionophores (monensin and lasalocid) on enteric CH4 emissions were evaluated in 36 Angus yearling steers (328 +/- 24.9 kg of BW) over a 16-wk period. Steers were randomly assigned to 6 dietary treatments of 6 steers each. The 6 diets were low-concentrate without ionophore supplementation, low-concentrate with monensin supplementation, low-concentrate with a 2-wk rotation of monensin and lasalocid supplementation, high-concentrate without ionophore supplementation, high-concentrate with monensin supplementation, and high-concentrate with a 2-wk rotation of monensin and lasalocid supplementation. Daily enteric CH4 emissions, as measured using the SF(6) tracer gas technique, ranged from 54.7 to 369.3 L/steer daily. Supplementing ionophores decreased (P < 0.05) enteric CH4 emissions, expressed as liters per kilogram of DMI or percentage of GE intake, by 30% for the first 2 wk and by 27% for the first 4 wk, for cattle receiving the high-concentrate and low-concentrate diets, respectively. Cattle fed a rotation of ionophores did not (P > 0.05) exhibit a greater decrease and did not (P > 0.05) have a longer period of depressed enteric CH4 emissions compared with cattle receiving monensin only. Ionophore supplementation did not (P > 0.05) alter total ruminal fluid VFA concentration; however, the acetate:propionate ratio and ammonia-N concentration in ruminal fluid were decreased (P < 0.001) from the time that ionophores were introduced to the time they were removed from the diets. Both monensin and the rotation of monensin and lasalocid decreased (P < 0.001) total ciliate protozoal populations by 82.5% in the first 2 wk and by 76.8% in the first 4 wk during which they were supplemented in the high-concentrate and low-concentrate diets, respectively. Original ciliate protozoal populations were restored by the fourth and sixth week of supplementation when cattle were fed the high- or low-concentrate diets, respectively. No significant change was observed thereafter. These data suggest that the effects of ionophores on enteric CH(4) production are related to ciliate protozoal populations and that ciliate protozoal populations can adapt to the ionophores present in either low- or high-concentrate diets. Rotation of monensin and lasalocid did not (P > 0.05) prevent ciliate protozoal adaptation to ionophores.

Effects of Weaning and Ionophore Supplementation on Selected Blood Metabolites and Growth in Dairy Calves

Dairy calf weaning results in blood ketone concentrations in excess of mature rates of use and can result in excretion of ketones in urine representing a loss of energy. Lasalocid is frequently supplemented as an anticoccidial agent in calf starters; however, in mature ruminants it is known to alter molar ratios of ruminal volatile fatty acids (VFA). Effects of weaning transition and postweaning ionophore supplementation on body weight, dry matter (DM) intake, average daily gain (ADG), and blood concentrations of glucose, acetoacetate, beta-hydroxybutyrate (BHBA), lactate, pyruvate, nonesterified fatty acids (NEFA), VFA, insulin, and glucagon were examined using Jersey bull calves (n = 24) over 16 wk. Calves were blocked into groups of 2 according to birth date and weight and randomly assigned to receive either a commercial pelleted starter (control), or the same diet containing lasalocid (TRT; 83 mg/kg of DM). Calves were fed milk replacer from d 3 to 34 (d 3 to 20 = 454 g/d at 12% solids; d 21 to 34 = 568 g/d at 15% solids), from d 35 to 48 calves received both replacer (d 35 to 41 = 454 g/d; d 42 to 38 = 227 g/d) and free access to control or TRT starter, and from d 49 to 112 received ad libitum control or TRT. Body weight and jugular blood metabolite concentrations were measured and recorded weekly. Postweaning DM intake, average daily gain, and feed:gain did not differ between control and TRT calves. Glucose and NEFA concentrations did not differ between control and TRT, but declined with age. Insulin and glucagon concentrations did not differ between control and TRT, but glucagon concentrations increased with weaning. Total VFA significantly increased following introduction of solid feed at d 35 in both groups with an apparent 1-wk lag in TRT VFA increases compared with control. Jugular acetate and butyrate concentrations were greater in control calves than TRT calves during wk 7. Propionate concentrations did not differ between control and TRT at any time following weaning. Blood BHBA concentrations were greater in control than TRT during wk 8 and 9. Thus, consumption of starter supplemented with lasalocid delayed peak acetate and butyrate and lowered peak BHBA concentrations. However, supplementation at concentrations currently recommended for control of coccidiosis did not appear to be sufficient to enhance growth or efficiency during the wk 7 to 16 postweaning interval for this sample size.

Production and Health of Pasture-Fed Dairy Cattle Following Oral Treatment with the Ionophore Lasalocid

The aim of the study was to evaluate the effect of feeding the ionophore lasalocid on the productivity and health of seasonally calving, pasture-fed dairy cows. Dairy cows (n = 1020) from 4 herds were enrolled in a split-herd, prospective intervention study. Cows were blocked by breed and age, ranked on previous production, and then assigned to 2 treatment groups. Treatment cows were each exposed to 300 to 350 mg of lasalocid/d commencing 3 wk before and ending 18 wk after the start of the seasonal calving period. Milk production was determined on 3 occasions for each cow at approximately monthly intervals (herd tests 1 to 3), body condition score was determined fortnightly, and all disease occurrences were recorded. Lasalocid treatment increased milk volume milk protein and milk fat production by approximately 2%, without altering milk composition. Fewer lasalocid-treated cows than control cows (7.3 vs. 11.6%, respectively) were diagnosed with clinical mastitis. Lasalocid treatment of pasture-fed dairy cows resulted in reduced mastitis incidence and increased milk production without changes in body condition or negative effects on metabolic processes as monitored by metabolite concentrations.

An Alternative to Antibiotic-Based Drugs in Feed for Enhancing Performance of Broilers Grown on Eimeria Spp.-Infected Litter

Three trials were conducted to evaluate the effects of lasalocid, an anticoccidial feed additive (90.7 kg/ton); bacitracin, a growth-promoter (50 g/ton); and yeast culture residue (YCR) (1 kg/ton) on the performance of broiler chicks reared to 42 d of age on recycled litter. Recycled litter consisted of pine wood shavings containing droppings from chicks infected with 3 select strains of coccidia (Eimeria tenella, Eimeria maxima, and Eimeria acervulina). Response variables (BW, intestinal tract and litter coliform counts, cecal and liver relative weights, and litter moisture content) were recorded biweekly. Mean BW of chicks fed the diet supplemented with YCR was higher than that of the controls (P < 0.05) and comparable to that of the lasalocid-treated birds in all 3 trials. Mean BW of chicks in all treatment groups decreased uniformly as the litter aged and moisture content increased. The mean intestinal coliform population from YCR-treated chicks was lower (P < 0.05) than those of the control and lasalocid populations. The coliform count was consistently lower than that in chicks on a bacitracin-supplemented diet. Coliform counts from the control and lasalocid-treated birds did not differ. The litter coliform counts increased with increased use of the litter. Cecal and liver relative weights calculated from the chicks in trial 3 showed that only the liver was significantly affected by treatments. YCR appeared to be a viable alternative to bacitracin and lasalocid medication in enhancing growth of broiler chicks reared on recycled litter.

Effect of lonophore supplementation on selected serum constituents of sheep consuming locoweed

The effects of ionophore supplementation on selected serum constituents of sheep consuming locoweed were investigated. Sixteen sheep were allotted by weight to a 2x2 factorial arrangement of treatments: 1) no locoweed, no lasalocid, 2) no locoweed, 0.75 mg lasalocid/kg BW, 3) 0.5 mg swainsonine/kg BW, no lasalocid, 4) 0.5 mg swainsonine/kg BW, 0.75 mg lasalocid/kg BW. Swainsonine was provided by locoweed (Oxytropissericea), and sheep were fed a blue grama based diet at 2.5% BW for a 35 d treatment period. Diets were formulated to be isocaloric and isonitrogenous. Blood samples were collected on d 1, 7,14, 21, 31 and 35 to determine serum swainsonine concentration, alkaline phosphatase, total iron, aspartate aminotransferase, g-glutamyltransferase, and lactate dehydrogenase activity and total cholesterol, and triglyceride concentrations. No lasalocid by locoweed interaction (P > 0.4) was noted for any response variable measured. Average daily gains (P = 0.4) and orts (P = 0.7) were not affected by the treatments. No lasalocid treatment (P = 0.7) or day (P = 0.1) effect of serum swainsonine was observed. A locoweed by day interaction (P < 0.0001) of serum alkaline phosphatase was detected. Alkaline phosphatase levels were elevated (P < 0.01) for locoweed treated sheep at 24 h following initial exposure and remained elevated throughout the trail. Total iron was suppressed (P < 0.08) in locoweed fed sheep. A day effect (P < 0.02) was observed for serum iron. However, no linear, quadratic, or cubic effects of day were noted (P >0.2). A locoweed by day interaction (P < 0.0001) of serum aspartate aminotransferase and g-glutamyltransferase was detected. Aspartate aminotransferase levels were elevated (P < 0.0001) by d 7 for locoweed treated animals and remained elevated throughout the trial. g--Glutamyltransferase levels were suppressed (P < 0.0001) by day 7 for locoweed treated animals and remained suppressed throughout the trial. A locoweed by day interaction (P = 0.06) of serum cholesterol was detected. However, no linear, quadratic, or cubic effects of day were detected (P = 0.2). Lasalocid treatment had no effect on any serum constituent measured. Use of lasalocid in grazing animals should not increase the likelihood of locoweed intoxication.

Effects of dietary rice bran, lasalocid, and sex of calf on postpartum reproduction in Brahman cows

To determine the effects of dietary lasalocid and increased dietary fat on reproduction, multiparous Brahman cows (n = 68), body condition score (BCS) of 6.2 +/- 0.7 and BW of 500.9 +/- 42.6 kg, were randomly assigned within sex of calf to receive one of four rations. All treatment groups grazed Coastal bermudagrass overseeded with rye-ryegrass and were given ad libitum access to hay and water. The control (n = 17) group received 4.17 kg x d(-1) x cow(-1) of 4:1 corn:soybean meal. The rice bran (n = 17) group received 4.35 kg x d(-1) x cow(-1) of 3:1:1 corn:soybean meal:rice bran (5.2% dietary fat). The lasalocid (n = 17) group received the Control diet with the addition of 200 mg of lasalocid x d(-1) x cow(-1). The rice bran-lasalocid (n = 17) group received the rice bran diet with the addition of 200 mg of lasalocid x d(-1) x cow(-1). Diets were fed once daily from d 1 after parturition through the detection of first estrus. Weight and BCS of cows and BW of calves were recorded at 14-d intervals from d 1 after parturition through detection of first estrus and at weaning. Cows were bled on d 1, 3, 5, 7, and 14 and at weekly intervals until estrus and on d 7 and d 10 after estrus. Ovarian follicular populations were monitored by transrectal ultrasonography weekly from d 14 after parturition through detection of first estrus. Plasma 13-14-dihydro-15-ketoprostaglandin-F2alpha (PGFM) and progesterone (P4) concentrations were quantified using RIA. Concentrations of PGFM from d 1 to 7 and P4 concentrations on d 7 and 10 after estrus were not influenced (P > 0.10) by diet or sex of calf. Changes in BW and BCS were not affected (P > 0.10) by diet. The number of medium-sized follicles tended to be greater (P < 0.06) in Controls than in cows on lasalocid or rice bran + lasalocid treatments on d 21. Cumulative return to estrus with a functional corpus luteum by d 60 postpartum was greater (P < 0.02) in the rice bran (70.6%) and lasalocid groups (76.5%) than in Controls (52.9%) or the group given rice bran + lasalocid (25.0%). Normal first estrous cycles were less likely (P < 0.07) to be exhibited in cows given rice bran + lasalocid than in other groups. Intervals from calving to corpus luteum formation, functional corpus luteum, and first P4 > or = 1 ng/mL were longer (P < 0.02) in cows given rice bran + lasalocid than in other cows. Combining increased dietary fat (5.2%) with lasalocid lengthened the time to reproductively important events.

Secretion of the trefoil factor TFF3 from the isolated vascularly perfused rat colon

The trefoil factor TFF3 is a peptide predominantly produced by mucus-secreting cells in the small and large intestines. It has been implicated in intestinal protection and repair. The mechanisms that govern TFF3 secretion are poorly understood. The aim of this study was, therefore, to evaluate the influence of neurotransmitters, hormonal peptides and mediators of inflammation on the release of TFF3. For this purpose, an isolated vascularly perfused rat colon preparation was used. After a bolus administration of 1 ml isotonic saline into the lumen, TFF3 secretion was induced by a 30-min intra-arterial infusion of the compounds to be tested. TFF3 was evaluated in the luminal effluent using a newly developed radioimmunoassay. TFF3 was barely detected in crude luminal samples. In contrast, dithiothreitol (DTT) treatment of the effluent revealed TFF3 immunoreactivity, which amounted to about 0.3 pmol min(-1) cm(-1) in the basal state. Gel chromatography of DTT-treated luminal samples revealed a single peak that co-eluted with the monomeric form of TFF3. TFF3 was not detected in the portal effluent. Bethanechol (10(-6)-10(-4) M), vasoactive intestinal peptide (VIP, 10(-8)-10(-7) M) or bombesin (10(-8)-10(-7) M) induced a dose-dependent release of TFF3. In contrast, substance P evoked a modest release of TFF3, whereas calcitonin gene-related peptide (CGRP), somatostatin, neurotensin or peptide YY (PYY) did not modify TFF3 secretion. The degranulator compound bromolasalocid, 16,16-dimethyl PGE2 (dmPGE2) or interleukin-1-beta (IL-1-beta) also evoked a marked release of TFF3. In conclusion, TFF3 in the colonic effluent is present in a complex. This association presumably involves a disulfide bond. Additionally, the present results suggest a role for enteric nervous system and resident immune cells in mediation of colonic TFF3 secretion.

Nutritionally directed compensatory growth enhances heifer development and lactation potential

The objectives of this study were 1) to examine the interactive influence of a compensatory nutrition regimen and lasalocid supplementation on dairy heifer growth performance and 2) to document the extent to which compensatory growth sustains lactation potential over the first two lactation cycles. Twelve Holstein heifers, weighing an average of 160 kg (about 6 mo of age) were randomly assigned to treatments arranged in a 2 x 2 factorial design. Treatment variables were two dietary regimens (control and stair-step compensatory nutrition) and two levels of lasalocid (0 and 200 mg/d). The control heifers were fed a diet containing 12% crude protein (CP) and 2.35 Mcal of metabolizable energy (ME) per kilogram of dry matter. The stair-step compensatory nutrition heifers were subjected to a phased nutrition regimen and reared according to an alternating 3-2-4-3-4-2-mo schedule. The first stair-step (prepubertal phase) consisted of energy restriction [17% CP and 2.35 Mcal/kg of ME] for 3 mo followed by realimentation (12% CP and 3.05 Mcal/kg of ME) for 2 mo. The second step (puberty and breeding) consisted of energy restriction for 4 mo followed by realimentation for 3 mo. The third step (gestation period) was energy restriction for 4 mo concluding with realimentation for 2 mo. Dry matter intake of heifers during the restriction phase was limited to 70% of the control intake. Heifers were given ad libitum access to a high energy density diet during realimentation to allow compensatory development. Stair-step heifers supplemented with lasalocid had the highest efficiency of growth (body weight gain/dry matter intake), suggesting synergistic metabolism of lasalocid with compensatory growth action. Compensatory growth induced during the last trimester enhanced metabolic status by increasing circulating insulin and decreasing triglyceride levels. Heifers on the stair-step regimen had a significant increase in milk yield during the first (21%) and second (15%) lactation cycles. These results support our thesis that compensatory growth induced during an allometric growth phase improves mammary development and energy and protein metabolic status of dairy heifers.

In vitro and in vivo efficacy of lasalocid for treatment of experimental cryptosporidiosis

In vitro viability of purified Cryptosporidium parvum oocysts, exposed for 30, 60, 90 and 120min to 0.27mg/ml lasalocid suspension was evaluated by inclusion or exclusion of two fluorogenic vital dyes and an excystation technique. Continuously, preventive and curative efficacies at different doses (9, 6.75, 5.625 and 4.5mg/kg body weight) and regimens of lasalocid against cryptosporidial infection were evaluated on an experimental neonatal mice model. In vitro assays demonstrated a decrease in the oocyst viability related to an increase in exposure time for exposure to the lasalocid suspension. The infection was eradicated when the suspension was administered with a dose of > or = 6.75mg/kg body weight. No apparent toxic effects were observed.

Efficacy evaluation of lasalocid plus roxarsone combination medication with different geographic field strains of Eimeria acervulina

Performance of broiler chickens medicated with lasalocid alone (at 125 ppm) or in combination with roxarsone (at 50 ppm) was evaluated in battery and floorpen trials after challenge with geographically different field strains of coccidia containing predominately the upper intestinal species Eimeria acervulina. No significant difference in bird performance measured at 6 days postinfection (PI) was observed between lasalocid plus roxarsone-medicated (L+RM) or lasalocid-medicated (LM) birds challenged in separate battery trials with mixed-species inocula from Alabama or Georgia containing 92% or 88% E. acervulina, respectively. In contrast, L+RM birds challenged in another battery trial with a Louisiana mixed-species inoculum containing 92% E. acervulina showed significant reduction in average weight gain at 6 days PI compared with LM-challenged birds. A floorpen trial done with the same Louisiana inoculum showed significant reduction in average bird weight gain at 27 and 35 days of age (6 and 14 days PI) for L+RM-challenged birds compared with both unmedicated-nonchallenged (UMNC) control and LM-challenged birds. The LM+R groups were significantly lower in average bird weight at 27 days of age than the unmedicated-challenged controls. Feed conversions (FCs) for L+RM birds were significantly higher than those for the UMNC control birds during time of challenge (21-27 days of age) and for the 1-to-27-day-of-age time period. No significant difference in FC was seen between the UMNC and LM groups. Results of this study showed that performance of broiler birds medicated with lasalocid plus roxarsone could vary for geographically different mixed-species challenge inocula that contained predominately E. acervulina.

Effects of lasalocid on performance of lactating dairy cows

Sixty lactating dairy cows (30 multiparous and 30 primiparous) were used in a completely randomized block design to determine the effect of lasalocid supplementation on dairy cow performance. Starting wk 2 prepartum and lasting through wk 17 of lactation, cows received one of three experimental diets. The experimental total mixed rations were control (CD), control + 10 mg/kg of lasalocid (CD + 10) and control + 20 mg/kg of lasalocid (CD + 20). The alfalfa-based control diet (40:60; forage:concentrate) was formulated to contain 18% crude protein, 35% nonstructural carbohydrates, 31% neutral detergent fiber, and 6.6% ether extract. Lasalocid supplementation linearly decreased dry matter intake (DMI) without affecting milk production or milk composition. Mean milk production and percentages of fat and protein were 30.0, 30.8, and 28.6; 3.56, 3.51, and 3.63; 3.06, 3.05, and 3.09; respectively for treatments CD, CD + 10, and CD + 20. Lasalocid supplementation decreased milk urea N (MUN) when compared to control cows, and increasing supplementation caused a significant linear decrease in MUN. For the primiparous cows, lasalocid supplementation decreased DMI and MUN while increasing body condition score and feed efficiency. Results from this study indicate that lactating dairy cows and, in particular, primiparous cows may benefit from lasalocid supplementation in terms of more efficient utilization of nutrients for milk production, reduced MUN levels, reduced body condition loss, and higher margin over feed cost.

Eating barley too frequently or in excess decreases lambs' preference for barley but sodium bicarbonate and lasalocid attenuate the response

We conducted experiments to determine whether preference for barley was affected when lambs ate various amounts of barley and whether lambs ate more barley when it contained lasalocid and sodium bicarbonate (NaHCO3), both of which attenuate acidosis. In Exp. 1, lambs were assigned to two treatments (six lambs/treatment). For 2 d, lambs in two treatments were offered either 400 or 1,200 g of rolled barley from 0600 to 0700 as a preload meal. A preference ratio [PR = barley ingested/(total amount of alfalfa + barley ingested)] was calculated based on lambs' intake when offered a choice of 200 g each of rolled barley and alfalfa pellets hourly from 0700 to 1100. After the preload meal, lambs in Treatment 1 (400 g preload) showed equal preference for barley (.52) and alfalfa (.48) for 4 h on d 1 (P > .05); their preference for barley was less after the meal of barley on d 1 (.52) than on d 2 (.72), but their preference for barley declined between h 3 (.81) and 4 (.55) of d 2 (P = .11). Lambs in Treatment 2 (1,200 g preload) showed a low preference for barley on d 1 (.29) and 2 (.19) (P < .001). In Exp. 2, lambs were assigned to four treatments (six lambs/treatment): 1) rolled barley + NaHCO3 (2%) + lasalocid (33 ppm); 2) rolled barley + NaHCO3 (2%); 3) rolled barley + lasalocid (33 ppm); or 4) rolled barley. Intake of barley by lambs offered NaHCO3 + lasalocid (Treatment 1) was greater (P = .07) than that by lambs offered NaHCO3 (Treatment 2), whereas intake by lambs offered lasalocid (Treatment 3) was similar (P > .05) to that by controls. We conclude that eating barley too frequently or in excess caused a decrease in lambs' preference for barley and that NaHCO3 and lasalocid attenuated the aversion.

Sheep fed grain prefer foods and solutions that attenuate acidosis

We conducted experiments to determine whether lambs fed grain prefer foods and solutions containing sodium bicarbonate (NaHCO3) and lasalocid, compounds capable of attenuating acidosis. In Exp. 1, we determined whether lambs fed barley preferred flavored rabbit pellets (RP) containing NaHCO3 and lasalocid. Lambs in two groups (n = 10/group) were fed increasing amounts of barley on d 1 to 12 (300 to 1,100 g) and again on d 23 to 34 (300 to 1,350 g). After ingesting barley on d 1 to 12, lambs were fed ground RP containing lasalocid and NaHCO3 (i.e., medicated) and flavored with either 2% onion (group 1) or 2% oregano (group 2). During d 23 to 34, lambs were fed unmedicated RP containing NaCl and flavored with either 2% oregano (group 1) or 2% onion (group 2). During preference tests on d 35 to 40, lambs fed grain preferred RP with NaHCO3 to RP with NaCl (151 vs. 96 g; P < .01). In the Exp. 2, we determined whether wheat ingestion affected consumption of aqueous solutions containing NaHCO3. In trial 1, 28 lambs were assigned to four treatments: 1) low-wheat + 2% NaHCO3, 2) high-wheat + 2% NaHCO3, 3) low-wheat + water, and 4) high-wheat + water. For 12 d from 0800 to 0830, lambs in treatments 1 and 3 were fed 300 g of wheat and lambs in treatments 2 and 4 were fed up to 1,300 g of wheat; fluids (NaHCO3 and water) were then offered from 0930 to 1230 daily. Lambs drank more NaHCO3 on the high- than on the low-wheat diet (1,332 vs 890 g; P = .03); water consumption was similar for lambs on the high- and low-wheat diets (1,675 vs 1,700 g; P > .10). In trial 2, lambs in treatments 3 and 4 were offered a solution containing 1.4% NaCl. For 13 d from 0800 to 0830, lambs in treatments 1 and 3 were fed 500 g of wheat and lambs in treatments 2 and 4 were fed up to 1,700 g of wheat. Lambs had access to fluids from 0800 to 1200 daily. Lambs drank nearly twice as much NaHCO3 solution on the high- than on the low-wheat diet (1,066 vs 572 g), whereas they drank only 1.4 times more NaCl solution on the high- than on the low-wheat diet (888 vs. 634 g; P < .001). Fewer lambs showed signs of acidosis in treatment 2 than in treatment 4 in trials 1 (2 vs 9) and 2 (7 vs 17). Collectively, these results are consistent with the hypothesis that lambs fed grain prefer substances that attenuate acidosis.

Residual activity of anticoccidial drugs in chickens after withdrawal of medicated feeds

Seven anticoccidial drugs commonly used in poultry (diclazuri), monensin, salinomycin, halofuginone, nicarbazin, robenidine, amprolium, and lasalocid) were tested for residual activity after withdrawal. In each test, the products were given at the recommended level to cages of 10 broiler chickens. Oral inoculation with coccidia was given after withdrawal of medication. Birds pretreated with 1 ppm of diclazuril and inoculated with Eimeria tenella after drug withdrawal had normal weight gain and very low lesion scores. Residual activity depleted gradually over several days, as shown by higher lesion scores when medication was withdrawn for up to 3 days before inoculation. Similar results were observed when young birds were inoculated with a mixture of E. tenella, E. maxima and E. acervulina, and also when birds were given diclazuril to market weight (6 weeks of age) and inoculated with a mixture of six species of Eiméria (The above species plus E. brunetti, E. mitis, and E. necatrix) after withdrawal of medication for 2 days. In contrast, there was no evidence of residual anticoccidial activity with nicarbazin, halofuginone, lasalocid, amprolium, salinomycin or monensin. Overall, the residual activity was unique to diclazuril.

Final-week performance of straight-run broilers as affected by early coccidiostat withdrawal followed by increased dietary salt

Three experiments were conducted to evaluate elevated dietary NaCl levels as a means of offsetting industry-observed reductions of growth, feed intake, and feed efficiency associated with early (35-d) coccidiostat withdrawal. In the first experiment, monensin (100 ppm) was withdrawn and dietary salt levels of 0.33, 0.48, 0.63, 0.78, or 0.93% provided from 35 to 42 d of age. Experiments 2 and 3 involved lasalocid (110 ppm) withdrawal and slat amounts of 0.33, 0.53, 0.73, or 0.93%. In all studies, a positive control of 0.33% salt and the coccidiostat was also given. Monensin withdrawal reduced body weight gain, which was not overcome by slat addition. Feed efficiency during the 1-wk period was improved to the level of the group receiving continued medication by salt amounts of 0.78% or above. In contrast to industry field observations, removal of lasalocid did not reduce body weight gain, feed intake, or water consumption, and elevation of salt levels resulted in no consistent improvements of weight gain, feed intake, or feed conversion. Water intake increased proportionally as salt concentration increased. Elevated salt levels do not appear to be a reliable means of offsetting reduced performance related to early coccidiostat withdrawal, nor were such performance problems demonstrable for lasalocid in these trials.

Effects of lasalocid in milk replacer of calf starter on health and performance of calves challenged with Eimeria species

Holstein bull calves (n = 48) were purchased from local sale barns at 3 to 7 d of age and were assigned randomly to a 2 x 2 factorial arrangement of lasalocid in milk replacer (0 or 80 mg/kg) and in calf starter (3 or 44 mg/kg of dry matter). On d 10 after arrival, calves were orally dosed with 100,000 Eimeria oocysts. Intakes of calf starter and milk replacer, body weight (BW), BW gain, excretion of fecal oocysts, and fecal scores were determined. Calves fed lasalocid in milk replacer consumed more calf starter, had greater BW gain, shed fewer oocysts in feces, and scoured less frequently and less severely than did calves fed no lasalocid or those fed lasalocid in calf starter alone. The combination of lasalocid in milk replacer and in calf starter did not improve performance above that of calves fed lasalocid in milk replacer alone. Low intake of calf starter prior to weaning may provide an insufficient amount of lasalocid to control effectively the effects of coccidiosis when calves are infected with Eimeria at an early age. Use of coccidiostats in milk replacers may reduce the effects of coccidiosis in young calves that are infected with Eimeria at an early age.

Control of coccidia in young calves using lasalocid

Thirty-six, 2- to 4-day-old Friesian bull calves were divided into 4 groups and fed milk replacer and calf starter pellets ad libitum in separate pens. Four treatments were applied; lasalocid in milk (1 mg/kg body weight/day) (M), lasalocid in starter (F), lasalocid in both milk and starter (M + F) and untreated (C). When the calves were about 2 weeks old they were each dosed orally with 550,000 sporulated Eimeria sp oocysts, mainly E zurneii and E bovis. The infection, detected by faecal excretion of oocysts, was suppressed in the M + F and M groups. There was significant excretion of oocysts in the F group but these calves did not show any clinical signs of coccidiosis. Untreated calves were affected with diarrhoea containing blood on the 24th day after inoculation. Body weight gain and intake of starter pellets was also depressed in the untreated calves during the time they were clinically affected. It is concluded that mixing lasalocid in milk replacer (or fresh milk) is an effective method of protecting young calves against early infection with coccidia.

Effects of lasalocid and cationomycin on the evolution of certain parameters in the blood plasma of sheep

Six adult sheep were fed at maintenance level, successively over three experimental periods, 1100 g of a roughage-rich diet without supplement or containing 33 mg kg-1 of lasalocid or cationomycin. The feed was administered in eight equal meals daily, every three hours. Blood samples were taken in each animal from the jugular vein at 10.00 hours, 16.00 and 22.00 hours, one hour after the animals were fed. The ionophores did not affect the plasma concentrations of glucose, free fatty acids, total amino acids, insulin, acetate, Ca or Mg. They decreased beta-hydroxy butyrate content (P < 0.05) and increased that of albumin (P < 0.05). Lasalocid alone significantly decreased uremia, but the significant threshold was only reached at 16.00 hours (P < 0.01). With this exception, the two ionophores had similar effects. Samples taken in peripheral blood appear to be too far from nutrient absorption sites to give a clear indication of the effects of these molecules on the products absorbed or metabolised in the digestive tract.

Effects of feeding lasalocid and monensin on digestive tract flow and partial absorption of minerals in sheep

Fifteen wethers (average BW 45.0 kg), fitted with abomasal and ileal cannulas, were fed a 70% concentrate diet alone or supplemented with 23 ppm of lasalocid or 23 ppm of monensin, DM basis. Wethers were fed 398 g of DM twice daily during a 10-d preliminary period, a 10-d total collection period, and a 6-d digesta collection period. During the total collection period, feed, feces, and urine were collected daily and composited. During the digesta collection, abomasal and ileal digesta and feces were collected at 12-h intervals, advancing 2 h each day, and composited. Feeding lasalocid and monensin increased (P < .01) urinary Mg excretion 17% and 19%, respectively. Lasalocid and monensin did not alter Ca and P metabolism. Feeding lasalocid decreased (P < .05) urinary excretion of Na 29%, whereas feeding monensin tended (P < .10) to increase it, compared with sheep fed the control diet. The effects of lasalocid and monensin were different for several variables compared with controls. Lasalocid and monensin altered absorption at different sites, overall absorption, and retention of minerals in sheep.

Anticryptosporidial activity of lasalocid and other ionophorous antibiotics in immunosuppressed rats

The anticryptosporidial activities of three ionophorous antibiotics were assessed in dexamethasone-immunosuppressed rats infected with Cryptosporidium parvum. When administered prophylactically, lasalocid prevented infection in a dose-dependent manner, whereas monensin and salinomycin were ineffective. Therapeutically, lasalocid eliminated established overt infections of the intestine, although infection persisted in the common bile duct and intestinal infection recurred after lasalocid treatment was stopped. These findings suggest that lasalocid is a potentially useful anticryptosporidial agent but that long-term continuous administration may be necessary in the immunocompromised host.

Effect of feeding lasalocid to pregnant ewes experimentally infected with Toxoplasma gondii

Sixteen 50 day gestational ewes were fed lasalocid at the rate of 30 g t-1 and were orally inoculated with 100 infective Toxoplasma gondii oocysts 5 days after beginning feeding of lasalocid. Seventeen control ewes were similarly inoculated with T. gondii and were not fed lasalocid. The rate of abortion and neonatal mortality in both treated and untreated ewes was similar, indicating that feeding lasalocid was not effective in preventing T. gondii abortion in sheep.

Oocysts of Eimeria in the litter of broilers reared to eight weeks of age before and after withdrawal of lasalocid or salinomycin

Forty-six broiler houses were examined for the presence of oocysts of Eimeria in the litter before and after withdrawal of lasalocid or salinomycin from the feed. A decrease in number of small oocysts (Eimeria acervulina or Eimeria mitis) was observed following withdrawal of medication. Numbers of medium-sized oocysts (probably Eimeria tenella) remained the same, but an increase in large oocysts (Eimeria maxima) was recorded. No lesions attributable to Eimeria tenella were found in the ceca of birds after withdrawal of the drug. More small- and medium-sized oocysts were found at sites with new litter than at sites where the litter had been employed for previous flocks. No difference in the number of oocysts was found, whether birds were reared on oak shavings or a mixture of pine shavings and rice hulls. The number of oocysts was positively correlated with the moisture content of the litter, but there was no correlation between oocysts present and the final BW or feed conversion of the birds. Moisture levels were highest (after withdrawal of drug) for new litter or oak shavings. There was no correlation between moisture content of the litter and BW or feed conversion.

Response of young dairy calves with lasalocid delivery varied in feed sources

Growth, age at weaning, fecal scores, and blood metabolites of young dairy calves were measured to determine the most effective method of lasalocid administration. Forty Holstein bull calves were blocked by date of birth and assigned randomly to one of four treatment groups: no lasalocid; lasalocid in starter; lasalocid in prestarter and starter; or lasalocid in milk, prestarter, and starter for a 12-wk period. Calves were fed milk twice daily until they consumed 227 g/d of prestarter, at which time the p.m. milk feeding was discontinued, and starter was offered for ad libitum intake as a mixture with the 227 g/d of prestarter. When total dry feed consumption reached 1.3% of birth weight, the calf was weaned. When the calf was 5 wk of age, the prestarter was discontinued. Daily gain tended to be greatest during the first 6 wk for the calves receiving lasalocid in milk, prestarter, and starter. These calves also were weaned with less variation in days to weaning. By wk 8 through 12, there were no differences in gain among the treatment groups.

The quality of meat of lambs fed with feeds containing lasalocid

The aim of the research was to determine the quality of meat of lambs fed with feeds containing lasalocid. It was ascertained that lasalocid added in the quantity of 50 mg per animal and day to the feed during the whole period of fattening considerably increased the protein content in the longest back muscle in lambs. The addition of 50 mg lasalocid to the feed considerably lowered the fat content in the muscle. The muscle of lambs receiving 50 mg of lasalocid had the best water binding capacity and thus was most suitable for the production purposes. Lasalocid influenced significantly and advantageously the intensity of colour of the muscle.

Long-term supplementation of lasalocid-sodium for beef bulls during grazing and subsequent finishing period

117 white-red beef bulls were involved to investigate the effect of lasalocid-sodium when fed either during the grazing period, or the finishing period, or during both subsequent periods. The ionophore was fed at 250 mg daily per head incorporated in 1 kg dry sugar beet pulp on pasture and at 65 mg per kg concentrate afterwards (corresponding with 27 ppm in the ration DM). The finishing diet consisted of maize silage ad libitum and 0.75 kg concentrate per 100 kg liveweight per day. On pasture lasalocid significantly increased daily gain form 0.6 to more than 0.7 kg, without affecting the grazed area per animal. During the finishing period growth rate was only slightly affected by lasalocid, but feed intake was reduced (P less than 0.05) and feed conversion improved (P less than 0.05). Feeding lasalocid permanently for more than 400 days did not reduce these positive effects. Cumulative daily gain, total feed intake per head and feed conversion were 1.12 kg, 2176 kg dry matter (DM) and 4.70 kg DM. These figures amounted to 1.05 kg, 2283 kg DM and 5.16 kg DM when no lasalocid was fed; 1.06 kg, 2141 kg DM and 4.87 kg DM when lasalocid was only fed during the finishing period and 1.09 kg, 2246 DM and 4.99 kg DM when lasalocid was only fed during the grazing period. Daily gains of 1.05 and 1.06 kg were significantly lower (P less than 0.05) than 1.12 kg. Most carcass data were unaffected, except fatness. The permanent feeding of lasalocid increased carcass fatness, mainly as the result of a higher final weight.

Intravenous administration of ionophores in ruminants: effects on metabolism independent of the rumen

The effect of i.v. administration of ionophores on metabolism in ruminants was investigated in two experiments. In Exp. 1, four Angus heifers were assigned randomly to receive i.v. monensin (18 mg, n = 2) or vehicle (control, n = 2). Samples were collected from indwelling vena cava cannulas from -60 to 240 min. Concentrations of K, Mg (P less than .05) and P (P less than .10) were lower and glucose (GLU) and free fatty acids (FFA) were higher (P less than .05) in monensin-treated than in control heifers. Serum insulin (INS) initially declined and subsequently increased (P less than .05) following monensin administration. A second experiment was conducted to determine the effect of a higher dose of monensin and the effect of lasalocid on minerals and metabolites. Angus (n = 3) and Hereford (n = 3) steers were randomly assigned to treatments in two 3 x 3 latin square designs. Treatments were i.v. administration of monensin, lasalocid or vehicle (ethanol) administered on three consecutive days. Administration of monensin, but not vehicle or lasalocid, resulted in ataxia, hypernea, polyuria and anorexia for approximately 2 h. Plasma concentrations of K, P and Mg were suppressed (P less than .05) by monensin, but not by vehicle or lasalocid administration. The decrease in K was preceded by a transient increase in K 15 min after administering monensin. Concentrations of GLU and FFA increased (P less than .05) following monensin administration. Concentrations of INS were lower from 60 to 120 min and greater at 180 and 240 min compared with -60 to 0 min from monensin administration (P less than .05). These results provide first evidence of an effect of monensin on metabolism in ruminants independent of alterations in ruminal microbial metabolism.

Safety of lasalocid in turkeys and its compatibility with tiamulin

An investigation involving 640 turkeys demonstrated that the inclusion of lasalocid continuously from day-old to 16 weeks of age, at levels up to 375 ppm in the feed, produced no adverse effects; furthermore, the inclusion of 125 ppm lasalocid in the feed was compatible with the administration of 250 ppm tiamulin in the drinking water continuously for five days to turkeys over the same age range.

Influence of lasalocid level on forage intake, digestibility, ruminal fermentation, liquid flow and performance of beef cattle grazing winter range

Three experiments were conducted to study the effects of lasalocid level on performance, intake, digestibility, ruminal fermentation and fluid flow of beef cattle grazing dormant, tallgrass prairie. In Exp. 1, 120 pregnant, mature beef cows of primarily Hereford breeding (avg wt = 471 kg) were randomly assigned to received 0, 100, 200 or 300 mg lasalocid X head-1 X d-1 in 1.82 kg supplement. Weight changes at 30, 60 or 90 d, condition score change and calf birth weight were not affected (P greater than .10) by lasalocid level. In Exp. 2, estimates of intake and digestibility were obtained with 40 pregnant, mature Hereford cows (avg wt = 474 kg) and 12 esophageal-cannulated, Hereford X Angus steers (avg wt = 225 kg), using Yb and indigestible acid detergent fiber as markers for fecal output and digestibility, respectively. Levels of lasalocid provided to cows and steers were similar, on a body weight (BW) basis, to those in Exp. 1 and corresponded to approximately 0, .22, .44 or .66 mg lasalocid/kg BW. Total diet and forage organic matter digestibility for beef cows decreased (P less than .01) at the .22 mg/kg BW level, but increased at the .44 and .66 mg/kg BW levels. Organic matter intake was not influenced (P greater than .10) by lasalocid addition. In Exp. 3, 16 ruminal-cannulated, Hereford X Angus steers (avg wt = 227 kg) were given the same lasalocid dosages per kg BW as in Exp. 2, and were used to study the effects of lasalocid on ruminal fermentation and fluid flow characteristics.(ABSTRACT TRUNCATED AT 250 WORDS)

Lasalocid toxicity in cattle: acute clinicopathological changes

Thirty-six steers (148 to 500 kg) divided into six equal groups were used in a toxic syndrome study of lasalocid and monensin given as a single oral dose. One group was given a placebo, a second group received monensin (25 mg/kg body weight) and the other four groups received lasalocid at 1, 10, 50 or 100 mg/kg body weight (bw). No toxic signs developed in cattle given placebo or lasalocid at 1 or 10 mg/kg bw dose. The earliest toxic signs were muscle tremors, tachycardia and rumen atony. After 24 h, the cattle were dehydrated, anorectic and had diarrhea. Deaths occurred between d 1 and 22.5 in the groups receiving lasalocid at 50 and 100 mg/kg bw and monensin. Altered values in blood leucocytes, erythrocytes, hemoglobin, hematocrit, total protein, albumin, creatinine, urea nitrogen, total bilirubin, creatine kinase, lactic dehydrogenase, calcium, chloride and inorganic phosphate occurred 1 d after dosing: urine pH and specific gravity also changed 1 d after dosing. Maximum changes occurred at d 3. Most of the changes were indicative of dehydration rather than specific organ damage.

Reduction of 3-methylindole production and prevention of acute bovine pulmonary edema and emphysema with lasalocid

A study was conducted to determine the dose of lasalocid that would effectively reduce ruminal conversion of tryptophan (TRP) to 3-methylindole (3MI) and prevent the development of acute bovine pulmonary edema and emphysema (ABPE). After adaptation to a maintenance diet for 3 wk, 20 mature beef cows were randomly divided into four groups of five cows each and fed 0, 200, 400 or 600 mg lasalocid X head-1 X d-1 in .5 kg ground barley for the 12-d experimental period. In vitro conversion of TRP to 3MI and indole by ruminal fluid and volatile fatty acid (VFA) concentrations were determined on d 0, 2, 4, 6 and 12. On d 6, an oral dose of .35 g TRP/kg body weight was given to induce ABPE, and ruminal production of 3MI and indole was determined at intervals thereafter. Formation of 3MI was sharply reduced (P less than .01) both in vitro and in vivo by lasalocid treatment at 200 mg X head-1 X d-1. Further suppression of 3MI production occurred as the lasalocid dose was increased (P less than .05). Linear (P less than .0001) and quadratic (P less than .002) components were determined for the relationship between lasalocid dose and 3MI production. Indole formation was variable, but tended to increase (P less than .05) with increasing lasalocid dose. Cows that received no lasalocid developed moderate to severe clinical signs of ABPE and three cows died of acute lung disease. Lasalocid treatment at all levels prevented ABPE. Lasalocid decreased ruminal acetate and butyrate, and increased propionate concentration (P less than .01).(ABSTRACT TRUNCATED AT 250 WORDS)

A study of the effects of replacing monensin ionophore with lasalocid ionophore in the field control of coccidiosis in broilers

The following conclusions are made from an introductory investigation on the use of the coccidiostat lasalocid on 11 production farms of an integrated broiler production organisation. In terms of the incidence of sub-clinical coccidiosis, no significant difference was found between the previous use of monensin and the use of lasalocid during the investigation. However, the incidence of coccidiosis decreased with the introduction of lasalocid. Despite the fact that on some farms sub-clinical coccidiosis was diagnosed, the production performance clearly improved with lasalocid. EBI figures significantly increased from 163.6 to 172.5. During the investigation, in which approximately 220,000 broilers were involved, litter quality did not differ from that of previous crops in which monensin had been used. Feathering of the broilers in the trial crops in which lasalocid was used was similar to that of previous crops.

Effect of N-5' on histamine release from rat peritoneal exudate cells induced by calcium ionophore and ATP

We studied the effect of N-(3,4-dimethoxycinnamoyl)anthranilic acid (N-5'), an orally applicable anti-allergic drug, on the histamine release induced by calcium ionophores (A23187 and X537A) and ATP from rat peritoneal exudate cells (PEC). X537A (0.1-33.3 micrograms/ml) induced histamine release in a concentration-related manner, and 2.0 micrograms/ml of X537A induced release to the same extent as allergic histamine release. Histamine release induced by 2.0 micrograms/ml of X537A increased with longer incubation time, reaching a peak of about 100% at 120 min. N-5' had no effect on histamine release induced by X537A at the concentrations used (1-1000 microM), but DSCG exhibited significant inhibition at 1-100 microM. A23187 (0.05-0.5 microgram/ml) induced histamine release in a concentration-related manner, and it seemed that 0.033 microgram/ml of A23187 induces the same degree of histamine release as the allergic one. A23187 induced rapid histamine release which attained maximum 1 min after the addition. N-5' exhibited a significant concentration-dependent inhibitory effect on histamine release induced by A23187, and DSCG also exhibited significant inhibition (10 and 1000 microM). N-5' significantly inhibited histamine release induced by 100 microM ATP. These results indicate that N-5' and DSCG effect the histamine release induced by ionophore A23187 and X537A by different manners, and they suggest the possibility that N-5' inhibits some Ca++-dependent processes in histamine release, including the influx of Ca++ into cells, which is a trigger of the A23187 and ATP effects.

Bromolasalocid (Ro 20-0006) antihypertensive ionophore

Bromolasalocid (Ro 20-0006) is a calcium ionophore with antihypertensive activity that does not belong to any known class of antihypertensive agents. Bromolasalocid produces a relatively flat systolic blood pressure dose-response effect in the spontaneously hypertensive rat. An intensive cardiovascular evaluation of bromolasalocid at the highest dose used in the dose-response study showed full hemodynamic compensation; there was a significant decrease in both mean arterial blood pressure and peripheral resistance without a significant decrease in cardiac index. The antihypertensive action of bromolasalocid lasts many days after termination of dosing. Bromolasalocid is specifically antihypertensive and does not decrease arterial blood pressure in normotensive animals or in animal models of hypertensive cardiovascular disease with normal pulse pressures. Bromolasalocid is not a vasodilator and appears to mediate its antihypertensive action by restoring compliance of the large conduit arteries. Both the derived arterial compliance index and the blood pressure-pressor response to the carotid occlusion reflex are enhanced in the dog perinephritis model of hypertensive cardiovascular disease treated with bromolasalocid. Bromolasalocid appears to reverse the damage to cardiovascular tissue caused by prolonged hypertension via an action on calcium perturbations in large artery smooth muscle cells.

Determination of bromo-lasalocid in plasma by high-performance liquid chromatography with fluorimetric detection

A rapid, sensitive, and specific high-performance liquid chromatographic (HPLC) assay was developed for the determination of bromo-lasalocid in plasma. The compound was extracted into isooctane-ethyl acetate (90:10) from plasma saturated with potassium chloride and adjusted to strongly alkaline pH. The residue of this extract was dissolved in methanol-2-methoxyethanol (95:5) and analyzed by HPLC on a 10-micrometer C18 column [mobile phase of methanol-water-2-methoxyethanol-1 M potassium phosphate buffer, pH 3.0 (90:10:2.5:0.2)] using fluorescence detection with excitation at 215 nm and emission at wavelengths greater than 370 nm. The overall recovery of the assay was 65%, with a limit of sensitivity of 0.1 microgram/ml. The method was used to obtain plasma concentration-time profiles in the dog following oral administration of bromo-lasalocid-ethanolate.

Efficacy of lasalocid sodium against coccidiosis (Eimeria zuernii and Eimeria bovis) in calves

Calves experimentally infected with Eimeria bovis and E zuernii were used in a controlled experiment to determine the anticoccidial activity of lasalocid sodium. Eleven-week-old Holstein calves were given an inoculum of 300,000 E bovis and 200,000 E zuernii oocysts; medication was initiated on the day of inoculation and continued for a 4-week period. The progress of parasitic infection was monitored with quantitative fecal oocyst examinations for the 6 weeks before calves were inoculated, and then in the 4-week treatment period and a 3-week observation period. The calves were given different doses of lasalocid sodium (0.5, 0.75, 1.0, and 3.0 mg/kg) and were compared with both nonmedicated inoculated calves and controls (nonmedicated, noninoculated calves). There were overall numerical reductions of oocysts produced in the medicated groups when compared with the nonmedicated inoculated controls.

Comparison of two forms and two levels of lasalocid with monensin on feedlot cattle performance

One growth and two finishing trials were conducted with beef steers to compare lasalocid sodium and monensin sodium. Pure lasalocid, mycelia-cake lasalocid and monensin, each added individually to commercial protein supplement blocks at 880 mg/kg, depressed (P greater than .05) block intake so that approximately 100 mg of each additive were consumed daily by each animal. Daily gain, feed intake and feed efficiency for steers receiving blocks containing additives did not differ from the corresponding measures for steers receiving control blocks. No differences were observed in diet dry matter digestibility, as determined with acid-insoluble ash as an internal marker. Both forms of lasalocid and monensin reduced (P greater than .05) the incidence and concentration of coccidia oocysts. By day 40, only one steer on each of the additive treatments was shedding oocysts (4.2% of additive-supplemented animals), compared with 41.5% of the control steers. During trial 2, steers fed pure lasalocid gained faster and more efficiently (P greater than .05) than those fed the mycelia-cake lasalocid, monensin or control diets. The improvement in feed efficiency over the control value was 10.0, 3.4 and 4.0% with pure lasalocid, mycelia-cake lasalocid and monensin, respectively (P greater than .05). Steers fed mycelia-cake lasalocid had higher (P greater than .05) dressing percentages than those fed pure lasalocid or monensin. Dressing percentage was the only carcass measurement affected. In trial 3, lasalocid at 30 and 45 g/ton and monensin at 30 g/ton improved (P greater than .05) feed efficiency by 7.5, 11.0 and 8.2%, respectively. No significant differences in incidence or concentration of oocysts were observed between treatment groups in trial 3, probably because steers were in slatted floor pens.

Lasalocid and monensin in finishing diets for early weaned lambs with naturally occurring coccidiosis

Early weaned male crossbred lambs (n = 90) with an average weight of 14 kg were used in 6 groups to evaluate the efficacy of monensin (22 mg/g of feed) and lasalocid (12.5, 25, 50, and 100 mg/kg of feed) on naturally occurring coccidiosis. Average 24-hour oocyst output at the start of the experiment ranged from 5.7 x 10(6) to 156.7 x 10(6) for monensin-treated and 100-mg lasalocid-treated groups, respectively. Monensin and lasalocid were effective against Eimeria ninakohlyakimovae of E ahsata. To day 103, body weight gains were similar for the 4 groups fed lasalocid (336 g/day) and averaged 6% higher (P greater than 0.05) than did gains in control and monensin-treated lambs. Feed efficacy averaged 9% higher (P less than 0.05) for lambs fed 25, 50, and 100 mg of lasalocid/kg of feed and 7% higher (P greater than 0.05) for lambs fed monensin and 12.5 mg of lasalocid/kg of feed. There were no treatment effects on digestibility, although lasalocid tended to increase (P greater than 0.05) crude protein digestibility (values were higher on day 76 than on day 28). Lasalocid and monensin were potent manipulators of rumen fermentation. Increasing the amount of lasalocid in the feed was associated with successive increases (P less than 0.05) in molar proportions of propionic acid and decreases (P less than 0.05) in acetic acid. Lasalocid and monensin controlled naturally occurring coccidiosis and improved performance in early weaned lambs (45 days old) under feedlot conditions.

Toxic effects of lasalocid in horses

Lasalocid was given to horses in a series of sequentially increasing single oral doses ranging between 5 and 30 mg/kg of body weight, with an appropriate washout period between treatments. One of the 5 horses died after a dosage of 15 mg/kg, 1 of 3 horses died after 21 mg/kg, 1 of 3 horses died after 22 mg/kg, and 1 of 2 horses died after 26 mg/kg. The LD50 of lasalocid for horses was estimated to be 21.5 mg/kg. Monensin was given to horses in a similar manner at dosages of 1, 2, and 3 mg/kg of body weight. One of the 2 horses died after a dosage of 2 mg/kg and 1 horse died after a dosage of 3 mg/kg. The clinical signs of toxicosis observed in horses given either drug were progressive and included depression, ataxia, paresis, and paralysis with partial anorexia. Intermittent profuse sweating was observed before death in horses given monensin.

Lasalocid for improved weight gains and control of Coccidia in lambs

Lasalocid at 25 mg/kg of feed was highly effective in reducing numbers of oocysts in feces of naturally infected ewes and lambs. Treated ewes were fed lasalocid-medicated feed before and after parturition, and the 17 lambs from these ewes also were fed medicated feed gained 5.26 kg more (P less than 0.05) than did the 17 nontreated lambs from nontreated ewes. Naturally infected lambs maintained in semiconfinement acquired coccidia infections between 23 and 64 (mean of 38) days after birth. A coccidiostat given before and during the time coccidia-naive lambs were first exposed to coccidia was necessary to achieve the greatest production response to treatment. When naturally infected feeder lambs (30.9 kg) maintained in semiconfinement were fed lasalocid-medicated feed at 25 mg/kg of feed or unmedicated feed for 91 days, no significant difference (P greater than 0.05) in rate or efficiency of gain was detected, even though lasalocid was highly effective against coccidia.

Evaluation of lasalocid in salt against ovine Coccidia

Lasalocid at a level of 0.75% in free-choice granulated salt was highly efficacious against naturally acquired coccidia infections in lambs maintained in semiconfinement. Treated lambs consumed 18 g of medicated salt/day, reflecting an average daily lasalocid dosage of 4.3 mg/kg of body weight. Treated lambs gained 5.7 kg more than did untreated lambs (P less than 0.01) during the 84-day experiment. Clinical signs of coccidiosis were not observed in treated or untreated lambs.

Compatibility and anticoccidial activity of lasalocid in combination with roxarsone and antibiotics against Eimeria mixed infection in chicks

Lasalocid at the concentration of .0075% (68 g/ton) with and without roxarsone 45.4 g/ton was fed in combination with the growth promotants bacitracin methylene disalicylate 200 g/ton, bambermycins 2 g/ton, lincomycin 4 g/ton, nosiheptide 2.5 g/ton, zinc bacitracin 200 g/ton g/ton, and virginiamycin 20 g/ton exhibited a high degree of anticoccidial activity against mixed Eimeria infection in chickens in 9 day challenged battery trials. In these short term challenge trials chicks fed lasalocid, and the lasalocid growth promotant combinations, performed significantly better (P < .05) for growth and anticoccidial efficacy than those fed the growth promotants alone, and the infected, unmedicated controls. In almost all instances, the lasalocid-roxarsone-antibiotic combinations allowed for numerical increases in gains, improvement in feed conversion, and numerical decreases in lesions (in some cases, statistically significant (P < .05) over chicks fed lasalocid alone and/or the lasalocid antibiotic combination. The growth promotants did not interfere with the anticoccidial activity of lasalocid. The growth promotants fed alone exhibited no anticoccidial activity. However, when roxarsone was combined with the antibiotics, the combination resulted in numerically improved performance, reduced mortality, and in most instances, statistically significant decreases in lesions (P .05) over the infected, unmedicated control.

Enhancement of the anticoccidial activity of polyether antibiotics in chickens by tiamulin

The anticoccidial activities of monensin and lasalocid have been studied separately and in combination with tiamulin, a new pleuromutilin derivative. Combinations of constant tiamulin concentration (.0125%) in drinking water with various levels of polyether anticoccidials (6.3 to 125 ppm) in feed and conversely of constant levels of anticoccidials with various concentrations of tiamulin were used. The prophylactic efficacy of these combined treatments in battery raised broiler chickens infected with Eimeria tenella was evaluated. Assessment of the parameters mortality, weight gain, dropping scores, lesion scores, and oocyst output showed that simultaneous application of tiamulin significantly improved the anticoccidial activity of the polyethers. As tiamulin alone is without anticoccidial activity, this phenomenon was considered to result from an interaction between tiamulin and the polyethers leading to a slower metabolic degradation of the latter. Thus tissue levels adequate for maximum anticoccidial activity would be attained with lower polyether dose levels. Experiments using isolated perfused rat liver showed that elimination of monensin was reduced by 60% in the presence of tiamulin.

Development of immunity to coccidiosis in chickens administered anticoccidials in feed

New combinations of techniques were employed for comparing the development of immunity of Eimeria tenella in chickens being medicated with 12 different anticoccidials. Broiler-type birds in batteries received a daily measured dose of E. tenella oocysts for 15 consecutive days while the drug was administered at the manufacturer's recommended level. Two or more tests of each drug gave the following ratings: strong suppression, monensin (121 ppm), salinomycin (80 ppm), lasalocid (75 ppm); moderate suppression, monensin (100 ppm), decoquinate (30 ppm), clopidol (125 ppm), and narasin (80 ppm); slight suppression, arprinocid (70 ppm), nicarbazin (125 ppm), and amprolium (125 ppm + ethopabate (4 ppm); no effect, robenidine (33 ppm), zoalene (125 ppm), and aklomide (250 ppm).

Effect of imidazole on ionophore-induced ocular hypertension

The effect of intraperitoneal injections of imidazole on the elevation of intraocular pressure produced by the topical application of the cation ionophores A23187 or X537A was studied in rabbits. Pretreatment with 200 mg./kg. imidazole completely inhibited the ocular hypertension induced by 1.0 percent A23187. The elevation of intraocular pressure produced by 0.5 percent X537A was not blocked by pretreatment with imidazole.

Effects of lasalocid and monensin in combination with roxarsone on lesion reduction and oocyst suppression in chicks infected with Eimeria tenella field isolates

The anticoccidial activity of lasalocid, monensin, and roxarsone, alone and in combination, was evaluated against eleven Eimeria tenella recent field isolates. Lasalocid was used at 0.0075. 0.01, and 0.0125% activity drug in feed; monensin at 0.0099 and 0.0121%; and roxarsone at 0.005%. Further studies with lasalocid 0.0075%, monensin 0.0099% and roxarsone 0.005 and 0.0025% combinations were carried out against three E. tenella field isolates selected from the aforementioned strains. Lasalocid and monensin each exhibited a high degree of anticoccidial activity at all concentrations tested. Lasalocid and monensin fed in combination with roxarsone showed, in addition to high anticoccidial activity a further reduction in gross lesions and oocysts production, more pronounced at 0.005% level of roxarsone than at 0.0025%, compared to either medication alone or the roxarsone combinations. These positive effects were noted with all strains tested. The practical aspects of these findings are discussed.

Laboratory studies with some recent anticoccidials

The activities of monensin, lasalocid and halofuginone against Eimeria tenella, E. brunetti and E. necatrix have been studied under laboratory conditions. Complete control of experimental infections in the chick, separable from toxicity, was not obtained with monensin, but was achieved with the other two compounds at levels of 150 and 6 ppm in the food respectively. All three compounds appear to inhibit coccidial development very early in the life-cycle, and to have a fairly rapid lethal effect, monensin and lasalocid more so than the febrifugine derivative. In vivo observations have been supplemented with in vitro studies. Some discussion of the difficulties of relating laboratory experiments to field performance is given.